News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is a fascinating gene therapy that can be controlled by an oral drug - the gene therapy is injected into the tumor and it inserts a gene that when activated by the oral drug produces IL-12, which is an immune enhancer.  The problem is too much IL-12 causes severe problems so there is a need to be able to control it. They use this oral drug to control it and can turn off the gene therapy if needed simply by stopping the oral drug. 

They announced the first use of it in a DIPG patient.  They used it on over 175 other patients with other cancers, mostly glioblastoma, with relatively good results.   I wish them luck!

 


Posted on: 07/09/2020

Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740